Systimmune

Novel therapeutic bi-specific, and multi-specific antibodies, antibody-drug conjugates

SI-B003 Clin2 solid tumors; GNC-038 Clin2 lymphoma, leukemia; GNC-035 Clin1 multiple cancers; GNC-039 Clin1 glioblastoma; BL-B01D1 Clin1 solid tumors; BL-MO2D1 Clin1 solid tumors; BL-MO7D1 Clin1 solid tumors; SI-F019 Clin1 COVID-19

SystImmune is developing novel therapeutics for cancer using bi-specific and multi-specific antibodies, as well as antibody drug conjugates (ADCs). Tumors are not just composed of cancer cells but of a modified tumor microenvironment. SystImmune is creating biologics that work through systematic intervention on tumor microenvironments to directly attack the tumor and activate the immune system. To do this, SystImmune is utilizing several advanced technology platforms involving protein engineering, antibody development and process development. In addition, SystImmune is building a global clinical development strategy to provide drug programs for multiple concurrent commercial opportunities.